Combating Residual Risk with Treatment Intensification: Focus on PCSK9 Inhibitors – A Care Team Forum℠

Activity Overview

This activity features an engaging video panel discussion with 3 renowned clinical experts and Charles—a patient living with familial hypercholesterolemia (FH). The lively exchange is enhanced with explanatory visuals; direct note-taking capability; interactive questions; and a full in-suit resource library. The panel will delve into topics covering safety/efficacy data for PCSK9 inhibitors (PCSK9-Is), 2018 ACC/AHA guideline updates, and patient selection for treatment intensification with PCSK9-Is. Faculty will examine key matters in patient care, provide illustrative patient case scenarios, pose practical solutions to common issues encountered in clinical practice, and Charles will provide insight into his experience with FH, its treatment, and his interaction with the healthcare system.

0.50 CE Credit(s)
Expires: May 14, 2020

Target Audience

The target audience for this activity is lipidologists, endocrinologists, cardiologists, internal medicine and family medicine physicians, NPs, and PAs who manage patients with hypercholesterolemia.

Learning Objectives

Upon successful completion of this education activity, participants should be better able to:

  • Use PCSK9 inhibitors to manage hypercholesterolemia based on patient characteristics, guidelines, MOA, and efficacy and safety data

Activity Faculty

underberg_1540606

James A. Underberg, MD, MS, FACPM, FACP, FNYAM, FASPC, FNLA

Clinical Assistant Professor, Medicine
NYU School of Medicine and NYU Center for CV Prevention
Director, Bellevue Hospital Lipid Clinic
New York, NY

ballantynerev_1540622

Christie M. Ballantyne, MD

Professor and Vice Chair, Research
Department of Medicine
Director, Center for Cardiometabolic Prevention
Chief, Sections of Cardiology and Cardiovascular Research
Baylor College of Medicine
Houston, TX

hess_1540630

Gregory P. Hess, MD, MBA, MSc

Instructor, Department of Emergency Medicine
Drexel University College of Medicine
Adjunct Senior Fellow, Leonard Davis Institute for Health Economics
University of Pennsylvania
Philadelphia, PA